Thus, we speculate that stimulating PPAR-γ signaling or enhancing carnitine homeostasis may have therapeutic benefits in conditions of endothelial dysfunction such as pulmonary hypertension, diabetes, and atherosclerosis. This evidence concerns the gene PPARG and pulmonary arterial hypertension.